Baird Maintains Outperform on Apellis Pharmaceuticals, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Colleen Kusy maintains an Outperform rating on Apellis Pharmaceuticals (NASDAQ:APLS) with a $100 price target.
June 28, 2024 | 5:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Colleen Kusy has reiterated an Outperform rating for Apellis Pharmaceuticals, maintaining a $100 price target. This suggests confidence in the company's future performance.
The reaffirmation of an Outperform rating and a $100 price target by a reputable analyst suggests positive sentiment and confidence in Apellis Pharmaceuticals' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100